Eric Chan, PhD’s Post

View profile for Eric Chan, PhD, graphic

Professor, NUS

Do we know why patients treated with GLP-1 medicines (Wegovy and Zepbound) for Type-2 diabetes or obesity, should inform the doctor involved if they have a planned surgery?🤔 This is because this class of medicines reduces the rate at which food is emptied from the stomach (aka gastric emptying rate). Consequently, patients feel full (aka satiety) and consume less food. 🥪 However, this would also imply that patients may have food in their stomachs during surgery despite having fasted! 😥 This is dangerous as food may enter the lungs (aka aspiration) and cause respiratory problems! 😥 If we are taking such medications, we need to inform our healthcare professionals before surgery! 😎 For more details, please refer to the European Medicines Agency link below: https://lnkd.in/gpTD-fDg

  • No alternative text description for this image
Dr.Manas Ranjan Sahoo., M.S.(Pharm),PhD

Asst Professor-NIPER Guwahati: R&D|QC|QA|Enterprenurship|NPD|Formulation-Expert|Botanical Research|Phytopharmaceuticals|Nutraceutical|Cosmetics|Ayurveda| Phytochemistry| FMCG,OTC&CPD|Eternal Learner

1mo

Very Informative and useful information . Thanks a lot for sharing .!

Mitchell K.P. Lai

Teacher & Researcher, Yong Loo Lin School of Medicine, National University of Singapore

1mo

Important point that I can add to my teaching notes! Thanks Prof!

See more comments

To view or add a comment, sign in

Explore topics